Imaging-pathology discordance, the phenomenon wherein imaging findings do not align with subsequent pathological evaluation, poses significant challenges in clinical practice. This review explores the prevalence, underlying mechanisms, risk factors, and clinical implications of such discordance, emphasizing the importance of a multidisciplinary approach and continuous learning to optimize patient outcomes. Drawing on recent evidence and guideline recommendations, the article provides clinicians with practical decision-making strategies and highlights emerging technologies that may reduce diagnostic discrepancies.
In modern medicine, imaging modalities such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) are indispensable for diagnosing a wide variety of diseases. However, despite technological advances, instances where imaging results conflict with histopathological findings remain not uncommon. These discordances can lead to diagnostic confusion, impact treatment planning, and alter prognostic assessments. Recognizing, investigating, and learning from imaging-pathology discordance is essential for improving diagnostic accuracy and patient care.
The incidence of imaging-pathology discordance varies across specialties and disease types. In breast cancer, for example, studies report discordance rates between 5% and 15% in core needle biopsies, especially for non-mass lesions or microcalcifications. In liver and lung lesions, discordance rates fluctuate depending on lesion size, imaging modality, and operator expertise. The burden is clinically significant: discordant findings may result in repeat biopsies, delayed diagnosis, unnecessary surgeries, or misclassification of disease severity, all of which contribute to increased healthcare costs and patient anxiety.
Imaging-pathology discordance may arise due to a variety of mechanisms. Sampling error is a major contributor, particularly when heterogeneous lesions are biopsied. Imaging limitations, such as poor resolution or artifacts, can obscure or mimic pathology. Furthermore, certain disease processes such as inflammatory changes, fibrosis, or post-treatment alterations may appear radiologically suspicious but lack malignant features histologically. Conversely, early-stage malignancies may be radiographically occult yet pathologically significant. Understanding these mechanisms is crucial for clinicians interpreting discordant results.
Several risk factors predispose to imaging-pathology discordance. Lesion characteristics, such as small size, deep location, or non-specific imaging features, increase the risk. Patient-related factors include obesity (which can limit imaging quality), underlying comorbidities (e.g., cirrhosis in liver imaging), and prior treatments (which may alter tissue appearance). Procedural factors such as suboptimal biopsy technique, inadequate sample volume, or inaccurate targeting also contribute. Awareness of these risk factors can inform pre-procedural planning and post-procedural interpretation.
Clinically, discordance may present as an unexpected benign pathology in a radiologically suspicious lesion, or vice versa. In breast imaging, for instance, a BI-RADS 5 lesion yielding benign pathology necessitates immediate review. In musculoskeletal tumors, radiographic evidence of aggressive disease with benign histology raises concerns for sampling error or rare tumor variants. Clinicians must maintain a high index of suspicion when clinical, imaging, and pathology findings diverge, and should initiate multidisciplinary discussions to resolve discrepancies.
The diagnostic approach to imaging-pathology discordance requires systematic correlation between clinical history, radiologic findings, and pathological evaluation. Repeat imaging, second-opinion pathology review, or additional targeted biopsies may be indicated. Multidisciplinary tumor boards play a pivotal role in adjudicating discordant cases, integrating expertise from radiology, pathology, surgery, and oncology. Advanced imaging modalities, such as contrast-enhanced MRI or PET-CT, may provide further characterization of indeterminate lesions. Documenting and communicating discordance is critical for patient safety and medico-legal protection.
Management strategies depend on the nature and clinical context of the discordance. For benign pathology in a lesion with high radiologic suspicion, most guidelines recommend repeat or excisional biopsy. If pathology identifies malignancy in a radiologically benign-appearing lesion, comprehensive staging and treatment planning are warranted. Shared decision-making with patients, clear documentation, and timely follow-up are essential. In some cases, surveillance may be appropriate, particularly when both imaging and pathology suggest low risk and the patient's comorbidities preclude intervention.
Emerging technologies aim to minimize discordance and improve diagnostic precision. Image-guided biopsy techniques utilizing real-time navigation, elastography, or molecular imaging are increasingly available. Digital pathology and artificial intelligence (AI)-driven image analysis show promise in identifying subtle histopathological features that may correlate better with imaging. Liquid biopsy and radiomics are also being explored as adjuncts to traditional diagnostic pathways, potentially allowing for earlier and more accurate detection of disease processes.
Current guidelines from organizations such as the American College of Radiology (ACR), College of American Pathologists (CAP), and National Comprehensive Cancer Network (NCCN) emphasize the need for radiologic-pathologic concordance assessment in biopsy protocols. They recommend systematic documentation, multidisciplinary review of discordant cases, and prompt re-biopsy or additional workup when indicated. Training programs increasingly incorporate discordance scenarios into educational curricula to foster critical thinking and improve diagnostic skills among trainees.
Imaging-pathology discordance represents both a diagnostic challenge and a valuable opportunity for clinical learning and system improvement. Understanding its epidemiology, risk factors, and mechanisms enables clinicians to anticipate, recognize, and address discordant findings effectively. Multidisciplinary collaboration, guideline-based management, and adoption of emerging technologies are essential for minimizing diagnostic error and optimizing patient care. By systematically learning from discordant cases, healthcare professionals can enhance diagnostic accuracy, patient safety, and clinical outcomes.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation